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Abstract 
 
Placental development is markedly abnormal in women bearing a fetus with trisomy 21, with defective 
syncytiotrophoblast (ST) formation and function. The ST arises from cytotrophoblast (CT) fusion and 
plays an essential role by secreting hCG, which is essential to placental development. In T21 
pregnancies, CT do not fuse and differentiate properly into ST leading to the secretion of an abnormal 
and weakly bioactive hCG. In this study, we report for the first time, a marked decrease in the number 
of mature hCG receptor (LH/CG-R) molecules expressed at the surface of T21-affected CT. The 
LH/CG-R seems to be functional based on sequencing that revealed no mutations or deletions and 
binding of recombinant hCG as well as endogenous hCG. We hypothesize that weakly bioactive hCG 
and lower LH/CG-R expression may be involved in the defect of ST formation. Interestingly, the 
defective ST formation is mimicked in normal CT cultures by using LH/CG-R siRNA which result in 
a lower hCG secretion. Furthermore, treatment of T21-affected CT with recombinant hCG overcomes 
in vitro the T21 phenotype, allowing CT to fuse and form a large ST. These results illustrate for the 
first time in trisomy 21 pathology, how abnormal endogenous hCG signaling impairs human placental 
development. 
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Introduction 
The human placenta is characterized by 
extensive invasion of the trophoblast in the 
maternal uterus, creating direct trophoblast 
contact with maternal blood (haemochorial 
placentation). In early pregnancy, 
cytotrophoblasts (CT) proliferate and invade the 
maternal endometrium to form the anchoring 
villi (1). Cytotrophoblasts also differentiate into 
a continuous multinucleated layer known as the 
syncytiotrophoblast (ST).  
 
Human chorionic gonadotropin (hCG) is 
produced by the trophoblast, and especially by 
the ST covering the chorionic villi and bathing in 
maternal blood (2). The syncytiotrophoblast 
plays an essential role during pregnancy by 
allowing fetomaternal exchanges and by 
secreting placental hormones into the maternal 
blood. In vivo and in vitro, the 
syncytiotrophoblast arises from cytotrophoblastic 
cell fusion and differentiation. Numerous factors 
regulate ST formation, in an autocrine or 
paracrine manner (see for review (3)), including 
hCG (4, 5), and oxidative stress related to 
overexpression of copper/zinc superoxide 
dismutase located on chromosome 21 (6, 7). The 
molecular mechanisms underlying CT fusion and 
differentiation are poorly understood, but 
proteins involved in cell adhesion (cadherin 11) 
(8) and cell-cell communication (connexin 43) 
(9) are directly involved. We also recently 
demonstrated the direct involvement of syncytin 
1, a human endogenous retroviral envelope 
glycoprotein (10). 
 
Very few of the genes involved in human 
placental development and trophoblast 
differentiation have been identified. In contrast, 
with the increasing number of transgenic and 
knock-out mice and rats, many of the genes 
involved in murine placental development have 
been characterized (see for review (11)). 
However, results obtained in mice are difficult to 
extrapolate to humans, owing to the specific 
features of human placental development (3). For 
instance, hCG does not exist in mice and rats. 
 
Anomalies in CT differentiation and cell fusion 
may lead to severe placental abnormalities. In 
trisomy 21-affected pregnancies, the CT fuse 
poorly or tardily and the resulting defect in ST 
formation is associated with a decrease in hCG 
synthesis and secretion (12). We recently 
demonstrated that hCG secreted by T21-affected 
CT is abnormally glycosylated (13), and Susan 
Fisher's group has described variable defects in 
CT differentiation along the invasive pathway 
(14). 
 
Trisomy of chromosome 21 (T21), which causes 
the phenotype known as Down’s syndrome, is 
the major known genetic cause of mental 
retardation, affecting about 1 in 800 live births. 
Screening strategies to identify women at an 
increased risk of bearing a T21 fetus are based 
on maternal age, ultrasound signs and maternal 
serum markers (15). Some of these markers, such 
as hCG, are of placental origin. The hCG level in 
maternal serum is abnormally elevated at 14–18 
weeks in pregnancies with a T21 fetus, for 
reasons that are largely unknown. 
 
HCG belongs to the family of gonadotrophin 
hormones, that also includes luteinizing hormone 
(LH), follicle-stimulating hormone (FSH) and 
thyroid-stimulating hormone (TSH) (16). These 
glycoprotein hormones are composed of two 
subunits, α and β. The α subunit, common to the 
other gonadotrophin hormones, is a 92-amino-
acid polypeptide with two N-linked 
oligosaccharides. β-hCG is a 145-amino-acid 
polypeptide with two N-linked oligosaccharides 
and four O-linked oligosaccharides (17). The 
action of hCG in stimulating CT fusion and 
differentiation is primarily mediated via the 
chorionic gonadotropin receptor (LH/CG-R), 
which can also bind hLH (4, 5, 18). When 
engaged by these hormones, the LH/CG-R 
couples to a number of G-proteins and activates 
adenylate cyclase, phospholipase C and ion 
channels, thereby stimulating the cAMP and 
inositol phosphate signaling cascades (19, 20). 
LH/CG-R, which has seven transmembrane 
domains, belongs to a subfamily of G-protein-
coupled receptors (21) also comprising the FSH 
receptor (FSH-R) and the TSH receptor (TSH-
R). The human LH/CG-R gene has been assigned 
to chromosome 2p21 (22). Its coding region is 
over 60 kb long, and it has been cloned in pig, 
mouse, rat and also human, in whom it is 
composed of 11 exons and 10 introns (16, 21, 23, 
24). LHR has been also cloned in fishes (25-28), 
monkeys (29), bears (30) and many other 
species. The presence of LH/CG-R in human 
placenta was first described by Alsat (31) and 
subsequently confirmed by other authors (32, 
33). We recently showed that LH/CG-R 
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expression is modulated during normal CT 
fusion and differentiation (34). 
To better understand the defective ST formation 
occurring in T21-affected pregnancies, we 
studied the involvement of the abnormal hCG by 
examining its function and receptor interaction. 
We found that T21-affected pregnancy is 
associated with a low LH/CG-R expression, and 
that the secreted abnormal hCG can bind to its 
receptor. This low LH/CG-R expression, 
together with the secretion of abnormal hCG, is 
involved in the defective ST formation, as 
specific inhibition of LH/CG-R expression by 
siRNA in normal CT mimics the T21 phenotype 
(defective ST formation). More interestingly, 
treatment of T21-affected CT in vitro with 
normal recombinant hCG overcome the T21 
phenotype, allowing CT to fuse and form a large 
ST. 
 
Materials and Methods 
Placental tissue collection. 
French law allows termination of pregnancy with 
no gestational age limit when severe fetal 
abnormalities are present. Placentas were 
collected at the time of termination, between 12 
and 35 weeks of gestation (amenorrhea), in T21-
affected pregnancies and gestational-age-
matched control pregnancies. Gestational age 
was confirmed by sonographic measurement of 
crown-rump length at 8-12 wk of gestation. 
Control pregnancies were terminated because of 
severe bilateral or low obstructive uropathies or 
major cardiac abnormalities. The karyotype of 
placental cells was determined in all cases (free 
T21 or normal). The study was approved by our 
local ethics committee. 
 
Trophoblast cell culture 
Cytotrophoblasts from normal and trisomic 
placentas were isolated as previously described 
(35). After sequential trypsin/DNase I digestion 
followed by Percoll gradient centrifugation, the 
cells were further purified by negative selection 
to obtain a trophoblast preparation not 
contaminated by other cells, by using 
monoclonal anti-human leukocytic antigen A, B 
and C antibodies (W6-32HL, Sera Lab, Crawley 
Down, UK) according to a published method 
(36, 37). This antibody reacts with most cell 
types (e.g. macrophages, fibroblasts, extravillous 
trophoblasts) but not with villous cyto- or 
syncytiotrophoblasts. Cytokeratin 7 
immunocytochemistry was used to confirm the 
cytotrophoblastic nature of attached cells: 95-
98% of the cells were positively stained. 
 
Hormone assay 
The hCG concentration was determined in 
culture medium at 24h and 72h by using an 
enzyme-linked fluorescence assay (Vidas 
System, BioMerieux, Marcy l’Etoile, France) 
with a detection limit of 2 mU/ml. All values are 
the mean ± SEM of triplicate determinations. 
 
HCG biological activity assay 
The biological activity of secreted hCG was 
tested on Leydig cells (MA-10 cells, a generous 
gift from Pr. M. Ascoli, University of Iowa, Iowa 
City, IA) as previously described (38). HCG 
levels were first assayed in trophoblast culture 
medium. Various amounts of culture medium 
were added as previously described (13). The 
results were expressed as the progesterone 
concentration per number of cells for each hCG 
concentration added to the control and T21 
trophoblast culture medium. Progesterone was 
assayed with the ACS180SE instrument (Bayer), 
a polyclonal antibody against hCG (A0231, 
rabbit anti-human, Dako©, Glostrup, Denmark at 
7µg/ml), and a polyclonal antibody against 
LH/CG-R (LHR H50, rabbit anti human, Santa 
Cruz biotechnology inc, CA, USA at 2µg/ml) to 
block the action of hCG on MA-10 cells. 
 
Immunoblotting 
Proteins (70µg) were solubilized in RIPA buffer, 
submitted to 7.5% SDS-PAGE and transferred to 
nitrocellulose membranes. The membranes were 
immunoblotted with a polyclonal antibody 
against human LH/CG-R (LHR-H50, rabbit anti-
human, Santa-Cruz Biotechnology Inc, CA, 
USA) at 2µg/ml, and the specific band was 
revealed by chemiluminescence (West Pico 
Chemiluminescent, Pierce, Rockford, IL, USA) 
after incubation with an anti-rabbit peroxidase-
coupled antibody (Jackson ImmunoResearch, 
Baltimore, USA). Actin was immunoblotted with 
a rabbit polyclonal anti-actin antibody (Sigma-
Aldrich, MO, USA, at 1:1000). 
 
Cross-linking and immunoprecipitation 
DTSSP (3,3’-Dithiobis [sulfosuccinimidyl-
propionate]) is a soluble, homobifunctional N-
hydroxysuccinimide ester (NHS-ester). This 
cross-linker is thiol-clivable and primary amine-
reactive. NHS-ester reactions with primary 
amines form covalent amide bonds that results in 
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the release of N-hydroxysuccinimide. To cleave 
the covalent bond, we used 10mM DTT at 37°C 
for 30min. 
Protein G Plus-Agarose (Immunoprecipitation 
Reagent, Santa-Cruz biotechnology inc, CA, 
USA) was pre-mixed with a polyclonal antibody 
to human LHCG-R (LHR-H50). Cells (106/well) 
were seeded in six-well plates and cultured as 
previously described, except for overnight 
serum-free cultures. After 24h of culture, 2mM 
DTSSP was added to the culture medium for 
30min at 25°C to cross-link hCG to LHCG-R. 
Stop solution (Tris/Glycine 20mM, pH 7.5) was 
then added at 25°C for 15min. The cells were 
then washed with PBS and scraped in ice-cold 
RIPA buffer. After sonication the cellular extract 
was transferred to the immuno-complex Protein 
G-antibody to human LHCG-R, incubated 
overnight at 4°C and washed four times in RIPA 
buffer. Proteins were reduced with 10mM DTT 
(sufficient to cleave the covalent bond), and 
eluted by heating at 60°C for 10min in 1x 
electrophoresis sample buffer (Bio-Rad 
laboratories, CA, USA). Aliquots were submitted 
to 7.5% SDS-PAGE and transferred to 
nitrocellulose membranes. Immunoprecipitates 
were treated with antibodies as described above. 
 
RNA extraction and RT-polymerase chain 
reaction (RT-PCR) 
Total RNA was extracted from trophoblastic 
cells after 24h of culture by using the Trizol® 
reagent (Invitrogen Life Technologies, CA, 
USA). RT-PCR was performed as previously 
described (34) using specific oligonucleotide 
primers based on the coding sequence of the 
LH/CG-R (NM 000233) (Fig. 3A): P1(+): 5'-CA 
GACTTTTGCATGGGGCTC-3', P1(-): 5'-GTG 
GCAGTGGTCATAGACTACAC-3', P2(+): 5'-G 
CATCTGTAACACAGGCATC-3', P2(-): 5'-CA 
TCTGGTTCAGGAGCACAT-3', P3(+): 5'-CA 
AGCTTTCAGAGGACTTAATGAGGTC-3', P3 
(-): 5'-AAAGCACAGCAGTGG CTGGGGTA-
3', Actin (NM 001101) (+): 5'-GTGGGGCGCC 
CCAGGCACCA-3' and Actin(-): 5'-CTCCTTA 
ATGTCACGACGATTTC-3'. 
RNA samples pretreated with DNAse I were also 
amplified as controls. Amplified products were 
analyzed by electrophoresis on 1.8% agarose gel, 
visualized with ethidium bromide, and 
transferred to membranes (GeneScreen, NEN 
Life Science Products Inc, MA, USA). The 
amplified cDNA was hybridized with three 
LH/CG-R-specific cDNA probes (P1, P2 and P3) 
radiolabeled with 32P by using a random priming 
method. P1 is specific for the LH/CG-R trans-
membrane and intracellular domains and spans 
positions 1300 to 2099 (position 1 corresponds to 
the A of the ATG start codon of the LH/CG-R 
coding sequence); P2 and P3 were specific for 
the extracellular domain, located from positions 
386 to 1055 and 199 to 845, respectively. After 
prehybridization for 4h at 60°C in 50% deionized 
formamide, 1% SDS, 2xSSC, 10% dextran 
sulfate, the membranes were hybridized at 60°C 
in the same buffer containing the specific 
LH/CG-R cDNA probes and were washed at 
55°C, twice in 2xSSC, 1% SDS for 30min, 
2xSSC containing 0.1% SDS for 30min, and 
2xSSC for 5min. The membranes were analyzed 
by Cyclone (Storage Phosphor System, Hewlett 
Packard. France). 
 
Cloning and DNA sequencing of LH/CG-R 
PCR products were eluted from agarose gel, 
cloned into the pCRII-TOPO vector and 
sequenced as previously described (34). 
 
Binding assay 
Trophoblastic cells (106/well) were seeded in six-
well plates and cultured as described above. 
After 24h of culture they were washed and 
placed 2h in DMEM without FCS, then placed in 
1ml of DMEM, 0.1% BSA, 1mM HEPES. To 
determine the time of 125I-hCG incubation for 
maximum binding, we performed a time-course 
study at 25°C (from 10min to 2h) with 0.5nM 
125I-hCG. Thirty minutes was the most effective 
time, corresponding to maximum binding of 125I-
hCG in trophoblastic cells (data not shown). For 
equilibrium binding experiments the cells were 
incubated for 30 min at 25°C with 0.5nM 125I-
hCG and with increasing concentrations of 
unlabeled hCG (from 10-12 M to 10-8 M, C6322, 
Sigma-Aldrich, MO, USA). At the end of the 
incubation period the cells were washed and 
scrapped, and bound radioactivity was counted. 
Assays were performed in triplicate. Data were 
analyzed by using the LIGAND fitting program 
(version 4.97) (39).  
125I-labeled hCG was prepared as described by 
Hunter (40), using chloramine T as the oxidative 
reagent, as previously described (34). 
 
Intracellular cAMP determination 
At 24h of culture, cells (106/well) were 
stimulated with increasing concentrations of 
hCG (from 10-12 M to 10-6 M, C6322, Sigma-
Aldrich, MO, USA) in the presence of IBMX (3-
isobutyl-1-methylxanthine) to prevent cAMP 
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degradation. Cells were frozen on dry ice and 
cAMP was extracted from with ice-cold 65% 
ethanol. The extracts were dried and kept at -
20°C until use. Cyclic AMP concentrations were 
determined with an assay kit (Amersham 
Biosciences, NJ, USA) as previously described 
(34). Assays were performed in sextuplet. To 
determine the optimum time of cAMP 
accumulation under hCG stimulation, we 
performed a time-course study (from 5min to 1h) 
by stimulating trophoblasts with hCG (10-12M to 
10-6M). The most effective stimulating time was 
20min (data not shown). We used a polyclonal 
antibody against hCG (A0231, rabbit anti human, 
Dako, Glostrup, Denmark at 7µg/ml) to block the 
action of hCG on trophoblasts. 
 
LH/CG-R siRNA protocol 
LH/CG-R siRNA was a Smartpool mix (4 
different LH/CG-R siRNAs pooled) purchased 
from Dharmacon (Lafayette, CO, USA). SiRNA 
transfection was performed using the 
DharmaFECT 2 siRNA transfection reagent 
(Dharmacon, Lafayette, CO, USA) according to 
the manufacturer’s protocol. Briefly, 5µl (20µM) 
of LH/CG-R siRNA (M-003681, Dharmacon, 
Lafayette, CO, USA) or scrambled siRNA (46-
2629, Invitrogen Life Technologies, CA, USA) 
was diluted in 245µl of OPTI-MEM (Invitrogen 
Life Technologies, CA, USA) and 4µl of 
transfection reagent (DharmaFECT 2) was 
diluted in 246µl of OPTI-MEM. The two 
solutions were incubated for 5min at room 
temperature then combined and incubated for 
20min at room temperature. The mixture was 
added to the cells (2.0x106/well) and incubated 
for 48h at 37°C in air-5% CO2. After transfection 
the medium was removed and kept for hormone 
assay. Cells were collected and used for 
immunoblot analysis. 
Transfection efficiency was determined by 
testing siRNA uptake by primary cytotrophoblast 
cultures. After 5 h of culture, cytotrophoblasts 
were incubated with a fluorescein-labeled 
dsRNA oligomer for 18 h, then washed three 
times in PBS, fixed at 24, 48 and 72 h of culture 
and analyzed by fluorescence microscopy. The 
dsRNA oligomer were taken up from the first 24 
hours (60% of cells were labeled) and the 
proportion of labeled cells then increased 
progressively with the time (75% at 48 hours, 
85% at 72 hours). Whereas the number of dead 
cells after transfection remains constant (∼10%) 
during the culture and at a very low rates. Nuclei 
were stained blue by using the Hœchst 33342 
reagent. A dead cell reagent (ethidium 
homodimer-I, staining dead cells red) was used 
to assed cell viability after transfection, visually 
or quantitatively. Both reagents are fluorescent 
compounds that bind to DNA; however, Hœchst 
33342 binds to DNA in living cells, while the 
dead cell reagent binds only to the DNA of dying 
cells. Transfected cells can be visualized by 
fluorescence microscopy, as they integrate the 
fluorescein-labeled dsRNA oligomer. This 
experiment enabled us to determine the optimum 
concentrations of siRNA and transfection 
reagents. 
 
Statistical tests 
Statistical analysis was performed using the 
StatView F-4.5 software package (Abacus 
Concepts, Inc., CA, USA). Values are presented 
as mean ± SEM. Significant differences were 
identified by using ANOVA, and p<0.05 was 
considered significant. 
 
Results 
Defective ST formation in T21 
cytotrophoblastic cells 
Mononucleated cytotrophoblasts isolated from 
normal placenta aggregate and fuse to form a 
syncytiotrophoblast at 72h of culture. In contrast, 
cytotrophoblasts isolated from T21-affected 
placentas aggregate but fuse poorly, forming a 
few small syncytiotrophoblasts after 3 days of 
culture (Fig.1A). With cells isolated from normal 
placenta, in vitro syncytiotrophoblast formation 
is associated with an increase in hCG secretion 
into the culture medium (Fig.1B), from 7.4±2.3 
(in mUI/ml/106 cells) at 24h to 1089±61 at 72h. 
With cells isolated from T21-affected placentas, 
the defective syncytiotrophoblast formation is 
associated with a significant lower (p<0.0001) 
hCG secretion into the culture medium compared 
to normal cells (16.8±9.5 and 366±28 
mIU/ml/106 cells at 24h and 72h respectively) 
(Fig.1B). 
 
Defective LH/CG-R expression in T21 
cytrophoblastic cells 
HCG secretion by the ST is lower in T21 than in 
normal cells. In order to evaluate the role of hCG 
and its receptor in ST formation, we first studied 
the expression of LH/CG-R mRNA in normal 
and T21-affected cytotrophoblasts at 24h of 
culture. We carried out semi-quantitative RT-
PCR experiments with three sets of primers (P1, 
P2 and P3; positions indicated in Fig.2A). To 
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avoid contamination by genomic DNA, each 
RNA extract was pretreated with DNAse I. 
Moreover, the primers of pairs P2 and P3 were 
located on separated exons. 
 
As shown in figure 2B, the 800-bp, 660-bp and 
647-bp fragments obtained with P1, P2 and P3 
respectively indicated that LH/CG-R mRNA was 
significantly less abundant in T21-affected 
cytotrophoblasts than in normal cytotrophoblasts. 
No significant difference was noted in the actin 
mRNA (control) level. To confirm the specificity 
of these RT-PCR results, amplification products 
were transferred to Nylon membranes and 
hybridized with 32P-radiolabelled probes. We 
used three probes specific for LH/CG-R, 
spanning the extracellular, transmembrane and 
intracellular domains (for positions see Materials 
and Methods). Hybridization confirmed the 
significant lower LH/CG-R mRNA expression in 
T21-affected cytotrophoblasts. No difference 
was noted with an actin-specific control probe. 
Normalization of LH/CG-R mRNA to actin 
mRNA confirmed the decrease in LH/CG-R 
mRNA levels in T21-affected cytotrophoblasts 
(Fig.2C). Using primer set P1, LH/CG-R mRNA 
levels were 1.23±0.26 (in arbitrary units) in 
normal CT compared to 0.6±0.1 in T21-affected 
CT (p<0.013). A similar decrease was observed 
with primer sets P2 (1.20±0.26 and 0.35±0.06; 
p<0.034) and P3 (1.42±0.12 and 0.54±0.28; 
p<0.043). Interestingly, the relative expression 
was similar with the three primer sets 
(respectively 2.0-, 3.4- and 2.6-fold). 
 
We then used western blot to determine LHCG-
R protein expression in extracts of normal and 
T21-affected CT, using the polyclonal antibody 
LHR-H50 (Fig.3A). Two major bands were 
observed: a 85-95 kDa band corresponding to the 
mature form of the LH/CG-R (noted m on 
Fig.3A) present at the cell surface, and a 65-75 
kDa band which is the precursor (noted p) of the 
cell-surface receptor (34) (for review see (41)). 
As shown in Figure 3A, the mature form of 
LH/CG-R was far less abundant in T21-affected 
CT than in normal CT, whereas no significant 
difference in actin expression was observed. 
Normalization of mature LH/CG-R protein 
expression to actin expression showed a 
significant difference (at least 68%) between 
normal CT and T21-affected CT (9.2±0.7 and 
2.9±1.4 arbitrary units; p<0.0038). 
 
To confirm the decrease in LH/CG-R mRNA and 
protein levels, we performed binding 
experiments with 125I-hCG at 24h of culture of 
normal and T21-affected CT (Fig.3B). Scatchard 
analysis showed that the number of 125I-hCG 
molecules bound per normal CT (3511±693) was 
significantly higher (p<0.04) than that in T21-
affected CT (1124±350). The difference in Kd 
values between normal CT (0.5±0.2nM) and 
T21-affected CT (0.4±0.2nM) was not 
statistically significant. These results indicate 
that T21 CT express 3 times fewer LH/CG cell-
surface receptors less than normal CT. However, 
the LH/CG-R molecule expressed at the surface 
of T21 CT bound 125I-hCG with the same affinity 
as the LH/CG-R on normal CT. 
 
The reduced level of functional mature LH/CG-R 
at the cell surface of T21-affected CT was 
confirmed by measuring cAMP production in 
response to increasing hCG concentrations, at 
24h of culture. As shown in figure 3C, at 10-10M 
hCG, corresponding to maximum cAMP 
accumulation, the ability of hCG to stimulate 
cAMP production in trophoblastic cells was 
significantly higher (p<0.007) in normal CT 
(222±3 fmol/mg of protein) than in T21-affected 
CT (164±10 fmol/mg of protein). Stimulation 
with epinephrin (used as a positive control) 
induced similar accumulation of intracellular 
cAMP in T21-affected CT as in normal CT, 
showing that the T21-affected CT were viable 
and that the reduced cAMP production was not 
due to increased apoptosis of T21 cells or to a 
defect in the cAMP pathway. 
 
These results clearly shown that LH/CG-R 
expression at the surface of trophoblastic cells is 
markedly reduced in T21-affected pregnancies. 
 
Specific inhibition of LH/CG-R expression by 
siRNA inhibits syncytium formation and hCG 
secretion by normal cytotrophoblastic cells 
We then tried to mimic with normal CT what we 
observed in T21-affected CT, by incubating 
normal CT with LH/CG-R siRNA. As shown by 
western-blot analysis (Fig.4B), LH/CG-R siRNA 
markedly reduced LH/CG-R protein expression. 
Normalization of LH/CG-R protein expression to 
actin expression showed 74% of inhibition 
compared to cells tranfected with scrambled 
siRNA (8.0±0.1 arbitrary units; p<0.002). A 
similar decrease (78% inhibition; p<0.002) was 
also found when we compared control non 
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transfected cells to cells transfected with LH/CG-
R siRNA. No difference was seen between non 
transfected cells (control) and cells transfected 
with scrambled siRNA, indicating that 
transfection had no effect on the decreased 
receptor expression. 
 
Specific inhibition of LH/CG-R expression by 
siRNA was associated with a strong decrease in 
CT fusion and differentiation. The histogram in 
Fig.4A shows that there were more mononuclear 
cells (58.5±0.2%) in cultures treated with 
LH/CG-R siRNA than in those incubated with 
scrambled siRNA (32.5±0.1%; p<0.005). 
Calculation of an apparent fusion index showed a 
2.1-fold decrease in fusion (53.3±7.1% of 
scrambled-siRNA-treated cells fused, compared 
to 25.0±0.6% of LH/CG-R siRNA-treated cells; 
p<0.017). LH/CG-R siRNA treatment led to a 
decrease in the number and size of syncytia. 
Similar results were obtained when LH/CG-R 
siRNA-treated cells were compared to non 
transfected control cells (data not shown). 
 
Interestingly, the decrease in syncytium 
formation observed when normal cells were 
treated with LH/CG-R siRNA was associated 
with a decrease of syncytium function. As 
illustrated in figure 4C, hCG secretion into the 
culture medium was far lower with LH/CG-R 
siRNA-treated cells than with scrambled-siRNA-
treated cells (59% reduction) or control cells 
(66% reduction). This result was not due to a 
difference in cell viability following transfection, 
as hCG secretion by control and scrambled-
siRNA-treated cells was similar. 
 
These results point to a direct role of LH-CG-R 
in CT fusion and differentiation during ST 
formation. 
 
LH/CG receptors of T21-affected trophoblasts 
bind endogenous weakly bioactive hCG 
We have shown that T21-affected CT bear a 
reduced number of LH/CG-R. We then analyzed 
the bioactivity of the endogenous hCG ligand by 
using the well established test of hCG function 
on MA-10 Leydig cells (38). HCG secreted into 
the culture medium at 72h by normal (n=3) and 
T21-affected trophoblasts (n=3) were used to 
stimulate steroid production by Leydig cells, 
which constitutively express LH/CG receptors. 
At equivalent hCG concentrations in the culture 
medium (from 2.5x10-11M to 10-10M), the ability 
of hCG secreted by T21-affected trophoblasts to 
stimulate Leydig cell progesterone secretion was 
significantly decreased (Fig.5A, upper panel). To 
emphasize this result, we quantified the 
production of intracellular cAMP by Leydig cells 
after stimulation with hCG from normal (n=3) 
and T21 (n=3) culture medium. In view of 
previous results, we used two hCG 
concentrations to stimulate Leydig cells: 0.1x10-
11M, which does not elicit progesterone 
secretion, and 5x10-11M, which leads to maximal 
progesterone secretion. The histogram in Fig.5A 
(lower panel) shows that stimulation with hCG 
secreted at 72h of culture by T21-affected 
trophoblasts was associated with significantly 
lower (at least 3-fold) cAMP production than 
was hCG secreted by normal trophoblasts 
(510±64 versus 1535±61 fmol/mg of protein; 
p<0.0001). Intracellular cAMP accumulation 
occurred after hCG stimulation, as no cAMP 
production was detectable when the culture 
media were preincubated with anti-hCG (Ab-
hCG) or anti-LH/CG-R (Ab-LH/CG-R) blocking 
antibodies before hCG stimulation. We obtained 
similar results when we used hCG secreted at 
24h by normal and T21-affected trophoblasts 
(data not shown). 
 
This reduction in progesterone secretion and 
cAMP production after stimulation with hCG 
secreted by T21-affected trophoblasts was not 
due to lesser binding of this hormone to its 
receptor. Scatchard analysis (Fig.5B) showed 
that hCG secreted by T21-affected trophoblasts 
bound to LH/CG receptors expressed by Leydig 
cells with the same affinity (Kd=0.13±0.01nM) 
as hCG secreted by normal trophoblasts 
(Kd=0.15±0.07nM). 
 
Our results clearly show that hCG secreted by 
T21-affected trophoblasts is less bioactive than 
normal hCG, and that this is not due to deficient 
binding to the LH/CG receptor, as expressed on 
Leydig cells. We then studied the interaction of 
the LH/CG-R expressed by T21-affected CT 
with endogenous hCG secreted by the same cells. 
For this purpose we cultured T21-affected CT 
and cross-linked the endogenous hCG secreted 
into the culture medium to its receptor to form 
hCG-LH/CG-R complexes. These complexes 
were immunoprecipitated (Fig.6) by using an 
anti-LH/CG-R polyclonal antibody (LHR-H50) 
and were then incubated in presence or absence 
of DTT. We used the DTSSP cross-linker agent, 
which is cleavable in the presence of DTT (used 
as a reducing agent). After immunoprecipitation 
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the complexes were probed with an anti-LH/CG-
R antibody (Fig.6, left). Without the reducing 
agent (-DTT), we observed a band at 
approximately 130-kDa, corresponding to hCG 
cross-linked to LH/CG-R. Presence of DTT 
(+DTT) disrupted the hormone-receptor complex 
and the band at 130-kDa disappeared; a band 
corresponding to the receptor alone then 
appeared at 90-kDa. To ensure that the 130-kDa 
band corresponded to hCG-LH/CG-R 
complexes, we used an anti-hCG polyclonal 
antibody to treat the previous 
immunoprecipitates (Fig.6, right). In non 
denaturing conditions, a 130-kDa band 
corresponding to hCG bound to the LH/CG-R 
and a smaller band (40-kDa), corresponding to 
total hCG, was observed. In reducing conditions 
only the 40-kDa band was observed. No 130-kDa 
band was found as hCG-LH/CG-R complexes 
were disrupted. The interactions and complexes 
observed in these experiments were specific, as 
no cross-reactions occurred in a range of control 
conditions (Fig.6, lower). 
 
These results show that T21 trophoblastic cells 
produce an abnormal hCG that is weakly 
bioactive but that can nonetheless bind its 
receptor LH/CG. 
 
Defective ST formation by T21 
cytotrophoblastic cells is overcome by 
recombinant hCG treatment 
Interestingly, as shown in figure 7A, addition of 
recombinant hCG (rhCG, 10-8M) to the culture 
medium of T21-affected CT induced 
syncytiotrophoblast formation. T21 CT cultured 
for 72h contained twice as many mononuclear 
cells in control conditions (76.2±0.6%) than 
when treated with rhCG (39.3±0.9%; p<0.0001). 
In other words, rhCG induced T21-affected CT 
differentiation and fusion, as more than 60% of 
the cells participated in syncytia formation 
(versus 23% of untreated cells) (Fig.7B). With 
T21 cells the percentage of syncytia containing 
10 to 50 nuclei rose from 1.6±0.3% with 
untreated cells (controls) to 13.0±1.7% with 
treated cells (+rhCG) (p<0.003). In contrast, the 
proportion of mononuclear cells observed at 72 h 
of culture of normal CT was not affected by 
rhCG (+rhCG: 15.8±1.2%, -rhCG: 17.2±0.4%; 
Fig.7B). Indeed, rhCG promoted the fusion of 
already formed syncytia, producing larger 
syncytia (Fig.7B); the percentage of syncytia 
containing more than 50 nuclei was significantly 
higher with treated cells than with control cells 
(p<0.0001). 
 
These results show that the defective cell fusion 
and differentiation of T21-affected CT may be 
overcome. More importantly, they show the key 
role of hCG in ST formation, as the addition of 
recombinant hCG to the T21 CT culture medium 
led to CT fusion and ST formation. 
 
Discussion 
Placental development is severely abnormal in 
women bearing a T21 fetus, with defective 
syncytiotrophoblast formation and function 
leading to the secretion of an abnormal 
hyperglycosylated hCG (12, 13). We show here, 
for the first time, that treatment of T21-affected 
cytotrophoblasts with normal or recombinant 
hCG restores their capacity to form a 
syncytiotrophoblast. This reversal of the T21 
phenotype indicates that T21 CT have all the 
equipment required to fuse and differentiate. The 
abnormal CT fusion and differentiation observed 
in T21-affected pregnancies may thus be due to 
impaired hCG signaling. This is supported by our 
observation that specific inhibition of LH/CG-R 
expression by siRNA in normal CT mimics the 
T21 phenotype (defective ST formation). 
 
In this study, we clearly show that LH/CG-R 
expression, present at the cell surface of the cells, 
was far lower on T21-affected CT than on 
normal CT, as shown by using several 
complementary methods and a well-
characterized model of human villous 
trophoblast differentiation in vitro. LH/CG-R 
mRNA and protein levels were lower in T21 
cells, as also observed in situ by means of 
immunohistochemical studies (data not shown).  
 
These results are in line with those reported by 
K. Nicolaides, who demonstrated in total 
placental extracts that LH/CG-R expression was 
significantly lower in T21 pregnancies than in of 
controls (42), whereas CV. Rao described 
stronger expression of LH/CG-R in T21 
placentas (43). This divergence may stem from 
the use of different approaches and tools. Rao 
quantified LH/CG-R immunostaining in total 
samples of placental villous tissue and may thus 
have over-estimated LH/CG-R expression, as the 
receptor is also expressed in Hofbauer and 
endothelial cells (44, 45) in villous stromal tissue 
and by intermediate trophoblasts (46). Moreover, 
experiments with radiolabeled probes, such as in 
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situ hybridization, use porcine cDNA that shares 
only 88% of the human sequence. In this study, 
we designed specific probes for the human 
LH/CG receptor in normal and T21-affected 
villous CT. In addition, we quantified the mature 
form of the receptor expressed at the CT surface, 
whereas the other authors quantified all LH/CG-
R isoforms. 
 
Scatchard plots clearly showed that the 
maximum number of hCG molecules bound per 
cell was significantly lower on T21-affected CT 
than on normal CT. This lower cell-surface 
receptor expression by T21-affected CT was 
confirmed by the lower cAMP production 
observed after stimulation with recombinant 
hCG. This decrease in cAMP production was not 
due to a loss of receptor affinity for the 
recombinant hormone, as recombinant hCG was 
able to bind to LH/CG-R on both normal and 
T21-affected CT with the same apparent affinity 
(same Kd values). Apart from the smaller 
number of LH/CG-R molecules expressed at the 
surface of T21-affected CT, the LH/CG-R seems 
to be normal, as sequencing revealed no 
mutations or deletions. Moreover, the receptor 
was functional and able to signal after 
stimulation with recombinant hCG. Indeed, 
replacing the abnormal endogenous hCG by the 
recombinant hormone in T21-affected CT 
cultures enhanced ST formation. This also 
implied that a functional hormone is necessary 
for ST formation. In other words, the secretion of 
abnormal hCG by T21-affected cells might be 
responsible for the defective CT differentiation. 
We have previously shown that hCG is 
hyperglycosylated in T21 pregnancies by using 
different lectins (13). Indeed, mRNA levels of 
two enzymes involved in the glycosylation 
pathway, sialyl-transferase-1 (which adds a sialyl 
group to antennary structures) and fucosyl-
transferase-1 (which adds a fucose to the first N-
acetyl-glucosamine of glycoproteins) were 
significantly higher in cultured trophoblasts 
isolated from trisomy 21 placenta {Frendo, 2004 
#285}. We show here that it is biologically less 
functional on cytototrophoblast differentiation. 
We also demonstrate here that this abnormal 
hormone is able to bind its receptor. 
 
One particularly interesting result is the 
differential effect of recombinant hCG on normal 
and T21-affected mononuclear CT (Fig. 1C). 
Recombinant hCG did not reduce the percentage 
of normal unfused mononuclear CT but rather 
induced the fusion of already formed syncytia 
with one another, leading to huge ST containing 
more than 100 nuclei. In contrast, recombinant 
hCG induced the differentiation of T21 CT into 
an ST. At 24h of culture, the percentage of 
unfused CT was higher than in normal placenta, 
suggesting that their maturation or differentiation 
is delayed. Recombinant hCG enhanced CT 
fusion and differentiation into ST, possibly 
through the induction of LH/CG-R expression at 
the CT surface. A similar form of regulation has 
been described for EGF, which upregulates EGF-
receptor mRNA and protein expression in human 
prostate cancer (47). Another possible 
explanation is that, in T21, despite the lower 
LH/CG-R expression, the level of expression is 
still sufficient (above a critical threshold of 
receptor density required to induce 
differentiation) and the defective differentiation 
is due to the abnormal secreted hCG molecules. 
By removing the latter from the culture medium 
and replacing them with recombinant hCG, we 
restored the CT fusion and differentiation 
process. However, even after stimulation with 
recombinant hCG the rate of fusion was never as 
high as that observed with normal cells, whether 
or not they were treated with recombinant hCG. 
This difference may be due to the lower number 
of LH/CG-R molecules expressed at the surface 
of T21 CT. Indeed, our results show that LH/CG-
R is directly involved in human trophoblast cell 
fusion and differentiation, as its inhibition by 
specific siRNA reduce trophoblast cell fusion. It 
appears that the hCG-LH/CG-R system acts as a 
positive feedback system: if hCG signaling is 
intact, then ST formation is increased and hCG 
production as well, resulting in increased ST 
formation. 
 
Screening strategies used to identify women at 
an increased risk of bearing a T21 fetus are 
partly based on maternal serum markers such as 
hCG. The hCG level in maternal serum is 
elevated during T21 pregnancies, for reasons that 
remain largely unknown. We demonstrate that, 
despite this increase, the autocrine/paracrine 
effects of hCG on the placenta are severely 
impaired owing to a loss of hormone function 
and reduced expression of the mature form of the 
LH/CG receptor at the cell surface. The 
conjunction of these two phenomena results in 
inadequate receptor-mediated signaling, leading 
to hCG accumulation in maternal serum. 
Abnormal receptor expression leading to 
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hormone accumulation has already been 
described in various systems (48-50). 
 
The main clinical relevance of this report is that 
it shows the significance of hCG in establishing 
and maintaining placental and fetal development 
during human pregnancy. We clearly 
demonstrate that, in pregnancies associated with 
a T21 fetus, the placenta secretes an abnormal 
and weakly bioactive hCG molecule that cannot 
correctly stimulate CT differentiation. In 
addition, the subnormal expression of functional 
LH/CG-R protein in the placenta of T21 
pregnancies may have far-reaching 
consequences. For instance, the rate of 
spontaneous abortion is high in T21-affected 
pregnancies. Aneuploidy might alter the fetal 
cells’ ability to differentiate properly. The 
morphological, phenotypic and functional 
differences among T21-affected trophoblastic 
cells may explain why a significant number of 
pregnancies end in spontaneous miscarriage. 
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Figure legends 
 
Figure 1: Defective ST formation by T21 cytotrophoblastic cells 
(A): Differentiation of CT into ST, at 24h and 72h of culture, with normal (N) and T21 cells. The cells 
were visualized by phase contrast microscopy (upper panel) and by immunostaining (lower panel) of 
the cellular membrane (cm) with an anti-desmoplakin monoclonal antibody. Nuclei (nu) were 
counterstained by DAPI. At 24h of culture, normal and T21-affected CT had aggregated. At 72h, 
normal CT had fused, as immunofluorescence staining of the cell boundaries disappeared, owing to 
the formation of a large syncytium (ST) containing many nuclei. T21 cytotrophoblasts were still 
aggregated and had not fused. (B): hCG secretion into the culture medium at the indicated times, in 
normal (N) and T21-affected cell cultures. Results are means ± SEM of three culture dishes. This 
figure illustrates one experiment representative of three. 
 
Figure 2: Defective LH/CG-R mRNA expression in T21 cytrophoblastic cells 
(A): Schematic representation of the LH/CG receptor, and location of primers used for this study. (B): 
Ethidium bromide-staining gel after RT-PCR. Amplified products were separated on 1.8% agarose gel 
and analyzed by densitometry. Primers P1, P2 and P3 generate 800-bp, 660-bp and 647-bp amplified 
fragments, respectively. Hybridization with 32P-labelled specific probes confirmed that the amplified 
fragments were part of the LH/CG-R. RT-PCR was done with total mRNA extracted from 
cytotrophoblasts obtained from 3 normal (N) and 3 trisomic (T21) placentas. (C): The histograms 
represent LH/CG-R mRNA normalized to actin mRNA after RT-PCR with primers P1, P2 and P3. 
The data are means ± SEM of four independent experiments similar to the one shown in (B). bp: base 
pairs. *: p<0.05. 
 
Figure 3: Defective LH/CG-R protein expression in T21 cytrophoblastic cells 
(A): western-blot analyses were performed with normal (N) and T21-affected trophoblast cell extracts. 
The polyclonal antibody LHR-H50 raised against the human LH/CG receptor yielded two major bands 
on SDS-PAGE: a 65-75 kDa band corresponding to the LH/CG-R precursor (p) and a 85-95 kDa band 
corresponding to the mature LH/CG-R (m) expressed at the cell surface. The table shows mature 
LH/CG-R protein expression (m) normalized to actin expression (43-kDa). The results are the mean ± 
SEM of five culture dishes. Fig.3A illustrates one experiment representative of five. (B): Scatchard 
analyses of 125I-hCG binding in vitro to normal and T21-affected trophoblasts. Binding was allowed to 
proceed for 30 minutes at room temperature, on normal () and T21-affected cells (), after 24 hours 
of culture. Apparent dissociation constants (Kd) and the maximum number of molecules bound per 
cell were calculated with the LIGAND program (table). Results are means ± SEM of five experiments. 
(C): Intracellular cAMP production by normal () and T21-affected cells () after stimulation with 
recombinant hCG (10-12M to 10-6M) or with a positive control reagent (epinephrin 10-3M), compared 
to non stimulated cells (0). To show the specificity of stimulation by hCG, we used an anti-hCG (Ab-
hCG) blocking antibody. Stimulation of normal trophoblasts was performed with 10-10M and 10-8M 
hCG in the presence or absence of the blocking hCG antibody. Figure 3C illustrates one experiment 
representative of three. **: p<0.01. 
 
Figure 4: Specific inhibition of LH/CG-R expression by siRNA reduces syncytium formation and 
hCG secretion by normal cytotrophoblastic cells 
(A): Normal cytotrophoblasts were transfected with scrambled or LH/CG-R-specific siRNA. The 
extent and number of syncytia were assessed by desmoplakin immunostaining and by determining the 
number of DAPI-stained nuclei. After 72h of culture mononuclear cells were counted and the fusion 
index was determined as (N–S)/T, where N is the number of nuclei in the syncytia; S the number of 
syncytia; and T the total number of nuclei counted. Results are expressed as percentages of the control 
fusion index. Larger syncytia were observed with cells treated with scrambled siRNA than with cells 
treated with LH/CG-R siRNA. (B): Western blot analysis of LH/CG-R expression in lysates of 
untransfected cells (control) and cells transfected with scrambled siRNA or LH/CG-R siRNA. 
LH/CG-R was detected with polyclonal antibody LHR-H50 raised against the human LH/CG receptor 
and standardized with an anti-actin polyclonal antibody. The histogram shows LH/CG-R protein 
expression normalized to actin expression. (C): Levels of hCG secreted into the culture medium at 72h 
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by untransfected cells (control) and by cells transfected with scrambled or LH/CG-R-specific siRNA. 
Results are expressed as the mean ± SEM, *: p<0.05; **: p<0.01; ***: p<0.001. Figure 4 illustrates 
one experiment representative among five. 
 
Figure 5: HCG secreted by T21-affected trophoblast binds LH/CG-R but is weakly bioactive 
(A, upper panel) MA-10 Leydig cells were stimulated with hCG secreted in the culture media of 
normal (N) and T21-affected cells. Various volumes of these media, corresponding to the indicated 
concentrations of hCG, were used to stimulate MA-10 cells. Progesterone was assayed in MA-10 
culture medium 3h later. To confirm the lesser bioactivity of T21 hCG, we determined the intracellular 
cAMP accumulation in MA-10 cells after stimulation with medium conditioned by normal (N) and 
T21-affected cells (A, lower panel). The specificity of stimulation by hCG was determined with anti-
hCG (Ab-hCG) and anti-LH/CG-R (Ab-LH/CG-R) blocking antibodies. *: p<0.05; **: p<0.01; ***: 
p<0.001. (B) Scatchard analysis of 125I-hCG binding to LH/CG receptors expressed by Leydig cells in 
the presence of hCG secreted by normal () and T21-affected cells (). The apparent dissociation 
constants (Kd) and maximum number of molecules bound per cell (table) were calculated with the 
LIGAND program. 
 
Figure 6: LH/CG-R of T21-affected trophoblasts binds endogenous hCG 
Endogenous hCG from normal (N) and trisomic (T21) cultures was cross-linked to its receptor by 
using DTSSP, a reversible and cleavable (in reducing conditions) cross-linker. Cellular extracts were 
purified with immobilized LH/CG-R antibody (LHR H50) on protein G Plus-agarose. LH/CG-R–hCG 
complexes were analyzed by SDS-PAGE in reducing conditions in the presence or absence of DTT 
and probed with anti-LH/CG-R antibody (+) (left panel) or anti-hCG antibody (+) (right panel). When 
anti-LH/CG-R was used as probe (left panel), in non reducing conditions (-DTT), extracts of normal 
(N) and T21-affected cells contained a 130-kDa band corresponding to the hormone/receptor complex. 
In reducing conditions (+DTT), the hormone/receptor complexes were disrupted and a 90-kDa band 
corresponding to LH/CG-R was observed. When anti-hCG was used to probe the immunoblot (right 
panel), in non reducing conditions (-DTT), hCG in the hormone/receptor complex (130-kDa) and free 
total hCG (40-kDa) were detected in extracts from normal (N) and T21-affected cells. In reducing 
conditions (+DTT), the hormone/receptor complexes were disrupted and only free total hCG (40-kDa) 
was observed. The observed interactions and complexes were specific, as no cross-reactions were seen 
between the buffer used for cell extract preparation and protein G-agarose beads alone or between cell 
extracts and protein G-agarose beads coated with rabbit IgG, in either reducing or non reducing 
conditions (lower panel). 
 
Figure 7: ST formation in T21 cytotrophoblastic cells is induced by recombinant hCG 
(A): Normal (N) and trisomic (T21) cytotrophoblasts were cultured for 72h in the presence (+rhCG) or 
absence (control) of 10-8 M recombinant hCG. After 72h of culture the cells were immunostained with 
an anti-desmoplakin monoclonal antibody and the nuclei were counterstained with DAPI. (B): 
Mononuclear cells were counted and the distribution of nuclei was evaluated as follows: 100 syncytia 
were scored and the nuclei were counted in each syncytium. Data (from one representative experiment 
among five) are expressed as the distribution of the number of nuclei per syncytium. Results are 
expressed as the mean ± SEM. **: p<0.01; ***: p<0.001; ND: non detectable. 
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